Submission of Matters to a Vote of Security Holders · Other Events
Item 5.07 Submission of Matters to a Vote of Security Holders On July 13, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual Meeting ”).…
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item
5.07 Submission of Matters to a Vote of Security Holders
On
July 13, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual
Meeting ”). At the close of business on June 16, 2026, the record date for the Annual Meeting (the “ Record Date ”), there were
77,122,584 shares of the Company’s Common Stock, par value $0.0001 per share (the “ Common Stock ”) issued and
outstanding. A total of 25,792,741 shares of Common Stock, constituting a quorum, were represented in person or by valid proxies at the
Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in
the Definitive Proxy Statement, filed with the Securities and Exchange Commission on June 25, 2026, are as follows:
Proposal
1. All of the seven (7) nominees for director were elected to serve until the 2027 annual meeting
of stockholders or until their respective successors
have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to
elect the seven (7) directors was as follows:
Directors For Abstain Broker Non-Votes
───────────────────────────────────────────────────────────────────────
Mark Wendland 25,781,710 11,031 0
Clay Kahler 25,490,487 302,254 0
Jill E. Sommers 25,782,510 10,231 0
William Wiley 25,781,103 11,638 0
Sean Galvin 25,756,323 36,418 0
Pamela L. Carter 25,782,586 10,155 0
Rishi Nangalia 25,782,393 10,348 0
Proposal
2. The appointment of Rosenberg Rich Baker Berman P.A., as the Company’s independent registered public accounting firm for
its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:
For Against Abstain
────────────────────────────────────────
25,780,986 3,980 7,775
Item 8.01Item 8.01 - Other Events
Item 8.01
Other Events.
On
July 15, 2026, during a special meeting of the Board of Directors, the Board elected the following directors to serve on its committees:
Audit
Committee: Sean Galvin (as the Chair), Jill E. Sommers and Pamela L. Carter.
Compensation
Committee: William Wiley (as the Chair), Clay Kahler and Rishi Nangalia.
Nominating
and Governance Committee: Jill E. Sommers (as the Chair), William Wiley and Pamela L. Carter.